Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5878064 | 0.97 | USP2 (0.32) | CCR6NR1H2NR1H3 | |
| SCHEMBL5876342 | 0.94 | CCR6 (0.35) | CCR6MEN1KMT2A | |
| SCHEMBL5876223 | 0.91 | SMN1; SMN2 (0.33) | CCR6NR1H2NR1H3MEN1ALDH1A1 | |
| SCHEMBL5877305 | 0.90 | CCR6 (0.35) | CCR6ALDH1A1 | |
| SCHEMBL5876220 | 0.90 | NR1H2 (0.34) | CCR6NR1H2NR1H3MEN1ALDH1A1 | |
| SCHEMBL5876012 | 0.89 | NR1H2 (0.36) | CCR6NR1H2NR1H3MEN1ALDH1A1 | |
| SCHEMBL5877420 | 0.89 | NR1H2 (0.32) | NR1H2NR1H3MEN1KMT2A | |
| SCHEMBL5878049 | 0.88 | SMN1; SMN2 (0.34) | CCR6NR1H2NR1H3MEN1ALDH1A1 | |
| SCHEMBL5876674 | 0.87 | USP2 (0.35) | CCR6NR1H2NR1H3MEN1ALDH1A1 | |
| SCHEMBL5876928 | 0.86 | CCR6 (0.34) | CCR6MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119115-B2 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | IDO1, IDO2, INMT | CCR6 1780/4885NR1H2 556/4885NR1H3 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.